IMRX

Immuneering

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/04/26

Business Summary

Immuneering is a clinical-stage biotechnology company focused on developing precision oncology therapies designed to target specific genetic drivers of cancer. The company generates value by advancing proprietary drug candidates through research and clinical development, with the ultimate goal of monetization via partnerships, licensing agreements, or commercialization. Its moat is rooted in its scientific platform and intellectual property, which aim to identify and inhibit previously undrugged or resistant cancer pathways. Cash generation is currently dependent on capital markets and strategic collaborations, with long-term upside tied to successful clinical validation and regulatory approval of its therapeutic candidates.

 


Analyze IMRX on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$356

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

1.6

EV / EBITDA

-3.2

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.27

Next Year EPS Growth Estimate

-$1.35

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-25.60%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

4

Altman Z-Score

14.1

Return on Invested Capital (ROIC)

-44.10%

Current Ratio

17.5

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze IMRX on TradingView

Gainseekers Quantitative Analysis

Summary

At a $356M market cap, IMRX screens as a high-risk, balance-sheet-secured biotech rather than a mispriced compounder. There is no P/E or Forward P/E, EPS is -3.2, and EPS next year is estimated at -$1.27, confirming this is a pre-profit story with no earnings visibility. However, the Altman Z-Score of 14.1 and a Current Ratio of 17.5 signal exceptional balance sheet stability and low near-term insolvency risk, which materially reduces financial distress risk despite operating losses. With Price/Book at 1.6, the market is valuing it modestly above net assets, suggesting investors are paying for optionality rather than cash flow—this is speculative growth with a strong liquidity cushion, not a proven earnings engine.

AI Exposure / Tech Reliance

As a Biotechnology company in Healthcare, IMRX operates in a sector that is structurally aligned with AI-driven drug discovery and precision medicine trends. Biotech platforms that integrate computational modeling and data-driven target identification are inherently positioned to benefit from AI acceleration. The sector’s reliance on complex biological data creates natural leverage to modern machine learning tools, enhancing pipeline efficiency over time.

The Bull Case

A value or GARP investor could justify a position purely on balance sheet strength and asymmetric optionality. The Altman Z-Score of 14.1 and Current Ratio of 17.5 indicate substantial financial durability, meaning dilution or distress risk is muted in the near term. Despite a negative ROIC of -44.10% and Operating Margin of -25.60%, the company maintains a mid-tier Piotroski F-Score of 4, suggesting operational metrics are not in complete deterioration. At a Price/Book of 1.6, investors are not paying an extreme premium for pipeline exposure, and with EPS expected to improve from -3.2 to -$1.27 next year, there is a visible—though still negative—trajectory toward reduced losses, which can catalyze multiple expansion if execution improves.

The Bear Case

The red flags are obvious and severe: EPS is -3.2, ROIC is -44.10%, and Operating Margin is -25.60%, meaning capital is being deployed at deeply negative returns. There is no P/E, no Forward P/E, and no PEG ratio, removing any conventional valuation anchor tied to profitability or growth efficiency. Sales Growth Next Year is listed as -$1.35, reinforcing the absence of a clean growth narrative, while Institutional Ownership sits at just $17.00, implying limited smart-money conviction. With Consensus Rating at 20.10% and a Mean Consensus Target Price of 1.43, sentiment does not suggest aggressive upside expectations, leaving the stock heavily dependent on binary clinical or strategic outcomes rather than financial momentum.

Market Sentiment & Smart Money

Short Interest %

20.10%

Analyst Consensus

1.43

Average Analyst Price Target

$17.00

Institutional Ownership %

50.70%

1-Year Beta

1.29

Insider Buying % (6 Mo)

17.80%%

Distance to 52-Week High

54.80%

Distance to 52-Week Low

501.80%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.